Infliximab therapy for pediatric Crohn's disease

G. Verès, Robert N. Baldassano, Petar Mamula

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Crohn's disease (CD) is a chronic inflammatory disease that may involve any part of the gastrointestinal tract, characterized by transmural intestinal lesion in a genetically susceptible host. Anti-TNF-α neutralising agent, infliximab, the chimeric monoclonal IgG1 antibody, is indicated for pediatric patients with CD and medically refractory luminal and fistulising disease. The present clinical practice for infliximab use is induction sequence of 5 mg/kg at 0, 2 and 6 weeks administered intravenously and followed by infusion every 8 weeks thereafter. Careful attention should be paid to the potential adverse events, especially infections and malignancy. Recently, fatal cases in young patients with hepatosplenic T-cell lymphoma treated with infliximab and concomitant purine analogs were reported. In this review the authors summarize the present knowledge of infliximab therapy in children with CD based on the available published literature.

Original languageEnglish
Pages (from-to)1869-1880
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Pediatrics
Crohn Disease
T-Cell Lymphoma
Therapeutics
Monoclonal antibodies
T-cells
Gastrointestinal Tract
Chronic Disease
Immunoglobulin G
Refractory materials
Monoclonal Antibodies
Infliximab
Pediatric Crohn's disease
Infection
Neoplasms

Keywords

  • Crohn's disease
  • Infliximab
  • Malignancy
  • Pediatric
  • Side effects

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Infliximab therapy for pediatric Crohn's disease. / Verès, G.; Baldassano, Robert N.; Mamula, Petar.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 12, 12.2007, p. 1869-1880.

Research output: Contribution to journalArticle

Verès, G. ; Baldassano, Robert N. ; Mamula, Petar. / Infliximab therapy for pediatric Crohn's disease. In: Expert Opinion on Biological Therapy. 2007 ; Vol. 7, No. 12. pp. 1869-1880.
@article{374b52a83961412b82710ca33d0a2332,
title = "Infliximab therapy for pediatric Crohn's disease",
abstract = "Crohn's disease (CD) is a chronic inflammatory disease that may involve any part of the gastrointestinal tract, characterized by transmural intestinal lesion in a genetically susceptible host. Anti-TNF-α neutralising agent, infliximab, the chimeric monoclonal IgG1 antibody, is indicated for pediatric patients with CD and medically refractory luminal and fistulising disease. The present clinical practice for infliximab use is induction sequence of 5 mg/kg at 0, 2 and 6 weeks administered intravenously and followed by infusion every 8 weeks thereafter. Careful attention should be paid to the potential adverse events, especially infections and malignancy. Recently, fatal cases in young patients with hepatosplenic T-cell lymphoma treated with infliximab and concomitant purine analogs were reported. In this review the authors summarize the present knowledge of infliximab therapy in children with CD based on the available published literature.",
keywords = "Crohn's disease, Infliximab, Malignancy, Pediatric, Side effects",
author = "G. Ver{\`e}s and Baldassano, {Robert N.} and Petar Mamula",
year = "2007",
month = "12",
doi = "10.1517/14712598.7.12.1869",
language = "English",
volume = "7",
pages = "1869--1880",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Infliximab therapy for pediatric Crohn's disease

AU - Verès, G.

AU - Baldassano, Robert N.

AU - Mamula, Petar

PY - 2007/12

Y1 - 2007/12

N2 - Crohn's disease (CD) is a chronic inflammatory disease that may involve any part of the gastrointestinal tract, characterized by transmural intestinal lesion in a genetically susceptible host. Anti-TNF-α neutralising agent, infliximab, the chimeric monoclonal IgG1 antibody, is indicated for pediatric patients with CD and medically refractory luminal and fistulising disease. The present clinical practice for infliximab use is induction sequence of 5 mg/kg at 0, 2 and 6 weeks administered intravenously and followed by infusion every 8 weeks thereafter. Careful attention should be paid to the potential adverse events, especially infections and malignancy. Recently, fatal cases in young patients with hepatosplenic T-cell lymphoma treated with infliximab and concomitant purine analogs were reported. In this review the authors summarize the present knowledge of infliximab therapy in children with CD based on the available published literature.

AB - Crohn's disease (CD) is a chronic inflammatory disease that may involve any part of the gastrointestinal tract, characterized by transmural intestinal lesion in a genetically susceptible host. Anti-TNF-α neutralising agent, infliximab, the chimeric monoclonal IgG1 antibody, is indicated for pediatric patients with CD and medically refractory luminal and fistulising disease. The present clinical practice for infliximab use is induction sequence of 5 mg/kg at 0, 2 and 6 weeks administered intravenously and followed by infusion every 8 weeks thereafter. Careful attention should be paid to the potential adverse events, especially infections and malignancy. Recently, fatal cases in young patients with hepatosplenic T-cell lymphoma treated with infliximab and concomitant purine analogs were reported. In this review the authors summarize the present knowledge of infliximab therapy in children with CD based on the available published literature.

KW - Crohn's disease

KW - Infliximab

KW - Malignancy

KW - Pediatric

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=37049037048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049037048&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.12.1869

DO - 10.1517/14712598.7.12.1869

M3 - Article

C2 - 18034652

AN - SCOPUS:37049037048

VL - 7

SP - 1869

EP - 1880

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -